To gain deeper insight into the antitumor activity of PLK1 inhibitors in EGFR-mutant NSCLC cells, we performed RNA-seq to profile differentially expressed genes (DEGs) in PC9 cells treated with the PLK1 inhibitor volasertib. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.